Colombia’s health ministry has delivered an ultimatum, giving Swiss multinational pharmaceutical company Novartis a couple of weeks to bring down the price of a popular drug used in cancer treatment. The government has threatened the company with ending its current monopoly on the drug by allowing local labs to produce generic versions.
Documents created by Colombia’s embassy in Washington have described an intense pressure from Pharma sector lobbyists in the US congress to bear down on Colombia’s government over the controversy. THe embassy has warned that any action breaking Novartis’ monopoly on the Gleevec-Glivec drug, used in the treatment of leukaemia and other blood cancers in Colombia and other countries, could jeopardize the US’s backing for Colombia’s entry into the Trans Pacific Partnership Agreement.
Colombian Health Minister Alejandro Gavíria, a trained economist, commented on the diplomatic pressure, saying this shows the lengths to which the pharmaceutical industry is willing to go in order to protect their interests. “They are very afraid that Colombia’s example might catch on in the region” said the minister.
Full Content: NTR Guadalajara
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI